产品
编 号：F151436
分子式：C30H46O3
分子量：454.68
分子式：C30H46O3
分子量：454.68
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 14021-14-8
产品详情
生物活性：
Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo.
体内研究：
Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss.Animal Model:BALB/c white female mice (20 g weight; 7-week-old) treated with Imiquimod
Dosage:10 mg/kg
Administration:i.v.; every other day; for 5 days
Result:Significantly reduced Imiquimod-induced psoriasis-like symptoms.
体外研究：
Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism. Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca2+ mobilisation and activation of Akt and MAPKs is also competitively inhibited. Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury.
Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo.
体内研究：
Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss.Animal Model:BALB/c white female mice (20 g weight; 7-week-old) treated with Imiquimod
Dosage:10 mg/kg
Administration:i.v.; every other day; for 5 days
Result:Significantly reduced Imiquimod-induced psoriasis-like symptoms.
体外研究：
Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism. Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca2+ mobilisation and activation of Akt and MAPKs is also competitively inhibited. Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备